Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron deficiency in children

M Pless, S A Lipton

    The New England Journal of Medicine
    |December 2, 1993
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

    ESMO open·2025
    Same author

    Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

    ESMO open·2023
    Same author

    Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].

    ESMO open·2022
    Same author

    Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

    ESMO open·2022
    Same author

    Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

    ESMO open·2022
    Same author

    A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same journal

    Ebola at 50 - Lessons for Outbreak Response and Preparedness.

    The New England journal of medicine·2026
    Same journal

    Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

    The New England journal of medicine·2026
    Same journal

    Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients. Reply.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients.

    The New England journal of medicine·2026
    See all related articles